TGTX logo

TGTX TG Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$65.16
+0.28 (+0.43%)

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant invest…

Market Cap: $9.85Bwww.tgtherapeutics.com

Price

No data yet.

Social Signal Score

56
5d
50
1 mentions
—
30d
59
9 mentions
—
60d
57
14 mentions
—
90d
59
18 mentions
—
news: 14 · rss: 3 · marketaux: 1

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 1Sell 1Strong Sell 0
Avg price target$80.5+23.5%
Low $78Median $80.5High $83
Current Consensus

Revenue

$259.94M+682236.26%
$38.0K$86.67M$173.30M$259.94M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$3.02
$2.92–$3.13
5 analysts
FY2026
$1.03-66% YoY
$0.80–$1.18
4 analysts
FY2027
$2.77+168% YoY
$2.30–$3.15
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael S. Weiss
Sector
Healthcare
Industry
Biotechnology
Employees
399
Beta
1.81
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
6.58
www.tgtherapeutics.com